News-Medical.Net August 5, 2024
Dr. Chinta Sidharthan

In a recent study published in Scientific Reports, researchers conducted a placebo-controlled, double-blind crossover field trial to examine whether the phytocannabinoid cannabigerol impacted mood, stress, and anxiety and caused any related adverse effects of cognitive or motor impairment.

Background

With the legalization of cannabis in various countries, cannabis growers are attempting to diversify their produce to meet the growing interest of cannabis consumers.

While delta-9-tetrahydrocannabinol, or THC, continues to be the main molecule of interest among cannabis users for its intoxicating effects, there is also a growing interest in some of the other non-intoxicating compounds in cannabis for their medicinal and analgesic effects.

However, this has also resulted in the unregulated isolation and marketing of various terpenes and phytocannabinoids as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Patient / Consumer, Provider, Survey / Study, Trends
988 Mental Health Hotline Failed to Boost Service Offerings
Suicide hotline has not led to increased mental health service access: Study
Private Equity Investors Are Still Laser-Focused on Behavioral Health Care
Private Equity in Behavioral Health: Compliance Champions or Cost-Cutting Villains?
Private equity-backed company acquires New York behavioral provider

Share This Article